Daptomycin in the treatment of invasive Gram-positive bacterial infections in children: Personal experience

Minerva Pediatrica

Volumn 65, Issue 2, 2013, Pages 173-178

  Palma, D M ^a   Giordano, S ^b   Neville Cracchiolo, A ^a   Zangara, V ^c   Coffaro, G ^a   Tetamo, R ^a  

^a ARNAS Ospedale Civico Di Cristina Benfratelli   (Italy)

^b Infective Disease Unit   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

Child; Daptomycin; Methicillin resistant Staphylococcus aureus

Indexed keywords

DAPTOMYCIN; TEICOPLANIN; VANCOMYCIN;

ADOLESCENT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; CARDIOMYOPATHY; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; FEMALE; HUMAN; INFANT; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MEDICAL RECORD REVIEW; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEWBORN; OUTCOME ASSESSMENT; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS EPIDERMIDIS INFECTION; STAPHYLOCOCCUS INFECTION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DAPTOMYCIN; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES;

EID: 84879596020     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Ardura MI, Mejias A, Katz KS, Revell P, McCracken GH Jr, Sánchez PJ. Daptomycin therapy for invasive Gram-positive bacterial infections in children. Pediatr Infect Dis J 2007;26:1128-32. (Pubitemid 350190945)
2. Daptomycin for injection. Full prescribing reference. Monograph: Cubicin. Lexington, MA: Cubist Pharmaceuticals; 2006.
3. European Public Assessment Report [Internet]. [cited 2012 November 19]. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/000637/human-med-000730.jsp&mid=WC0b01ac058001d124
4. Hieber JP, Nelson AJ, McCracken GH Jr. Acute disseminated staphylococcal disease in childhood. Am J Dis Child 1997;131:181-5.
5. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128-40.
6. Abdel-Rahman SM, Chandorkar G, Akins RL, Bradley JS, Jacobs RF, Donovan J et al. Single-dose pharmacokinetics and tolerability of daptomycin 8 to 10 mg/kg in children aged 2 to 6 years with suspected or proved Gram-positive infections. Pediatr Infect Dis J 2011;30:712-4.
7. Wang G. Increased vancomycin MICc for Staphylococcus aureus clinical isolates from a universitu hospital during a 5-year period. J Clin Microbiol 2006;44:3883-6. (Pubitemid 44737223)
8. Akins RL. Pharmacokinetics of daptomycin in a critically ill adolescent with vancomycin-resistant enterococcal endocarditis. Pharmacotherapy 2006;26:694-8. (Pubitemid 43673052)
9. Abdel-Rahman SM, Benziger DP, Jacobs RF, Jafri HS, Hong EF, Kearns GL. Single-dose pharmacokinetics of Daptomycin in children with suspected or proved Gram-positive infections. Pediatr Infect Dis J 2008;27:330-4. (Pubitemid 351483068)
10. Skiest D. Treatment failure resulting from resistance of Staphylococcus aureus to Daptomycin. J Clin Microbiol 2006;44:655-6. (Pubitemid 43222276)
11. Hogan H. Daptomycin therapy of GRAM positive bacteremia (GPB) in pediatric cancer patients. Presented at the International Immunocompromised Host Society Conference, Crans Montana, Switzerland, July 2-5, 2006.
12. Kaatz GW. Mechanism of daptomycin resistance in Staphylococcus aureus. Int J Antimicrob Agents 2006;28:280-7. (Pubitemid 44402994)